Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype

Drug (Brand/Generic)

CINQAIR (reslizumab)

Company

Teva Pharmaceuticals

Therapy Class

IgG4 Kappa monoclonal antibody

Current Indication

Severe asthma and eosinophilic phenotype

Market Sector

Respiratory

Development Status

Approved in the US, MAA under review in Europe and Canada
Expand

Go Top